Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B4ced4e8d5cbb92f238530997fb48da8a> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B4ced4e8d5cbb92f238530997fb48da8a NCIT_P378 "NCI" @default.
- B4ced4e8d5cbb92f238530997fb48da8a type Axiom @default.
- B4ced4e8d5cbb92f238530997fb48da8a annotatedProperty IAO_0000115 @default.
- B4ced4e8d5cbb92f238530997fb48da8a annotatedSource NCIT_C187042 @default.
- B4ced4e8d5cbb92f238530997fb48da8a annotatedTarget "An orally bioavailable, central nervous system (CNS) penetrating, mutant-selective covalent inhibitor of epidermal growth factor receptor (EGFR) exon 20 insertion (Ex20ins) activating mutations, with potential antineoplastic activity. Upon oral administration, EGFR Ex20ins inhibitor BLU-451 selectively targets, irreversibly binds to and inhibits the activity of EGFR Ex20ins and some other oncogenic point mutations. This prevents EGFR Ex20ins-mediated signaling. This may induce cell death and inhibit tumor growth in EGFR Ex20ins-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumors, plays a key role in tumor cell proliferation and tumor vascularization. BLU-451 is able to penetrate the blood-brain-barrier (BBB) and may therefore exert its activity against EGFR Ex20ins-driven CNS primary tumors and CNS metastases. BLU-451 does not inhibit the activity of wild-type (WT) EGFR. EGFR Ex20ins are oncogenic driver mutations that constitutively upregulate kinase activity." @default.